ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seeking to best an earlier deal, Endo International has offered to acquire Salix Pharmaceuticals for $175.00 per share in cash and stock. Last month, Salix, a specialist in gastrointestinal treatments, agreed to be acquired by Valeant Pharmaceuticals for $158.00 per share, or about $14 billion including debt. Valeant says it stands by its all-cash deal, “which delivers immediate and certain value to Salix shareholders.” Salix says it will review the new offer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X